Fecal Microbiota Transplantation for Clostridium difficile Infection: Systematic Review and Meta-Analysis

By Z. Kassam, Christine H. Lee, Yuhong Yuan, R. Hunt. American Journal of Gastroenterology, 2013

871 citations recorded by the source corpus.

Subfields: Gastroenterology, Infectious Diseases, Surgery

View Paper: https://www.semanticscholar.org/paper/0fc7cf4e6a83c4bd57abf31cb4423bf589c258dc

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Infectious Diseases

1. Guido Kroemer
2. L. Zitvogel

In Surgery

1. Guido Kroemer
2. S. Formenti
3. Nihal Hasan
4. Hongyi Yang

Citations in the corpus

• Microbiota in health and diseases (2022, background): “The most prominent results in the use of fecal transplantation for disease treatment have been in the treatment of recurrent Clostridium difficile infection (rCDI), with reported cure rates near 90%.(368) In 2013, FMT was approved by the FDA to treat rCDI.”
• European Society of Clinical Microbiology and Infectious Diseases: update of the treatment guidance document for Clostridium difficile infection. (2014, neutral): “[164,185–191].”
• Tracking microbial colonization in fecal microbiota transplantation experiments via genome-resolved metagenomics (2017, background): “Although a substantial number of studies report successful medical outcomes of FMT experiments [3, 7, 57, 58], a complete understanding of this procedure from the perspective of microbial ecology is still lacking.”
• The gut microbiome in health and in disease (2015, positive): “A meta-analysis to review the use of fecal microbiota transplant (FMT) for prevention of recurrent CDI identified 11 studies with 273 patients through 2012; the overall resulting efficacy was about 90% and no substantial FMT-related adverse events were reported [37].”
• Frozen vs Fresh Fecal Microbiota Transplantation and Clinical Resolution of Diarrhea in Patients With Recurrent Clostridium difficile Infection: A Randomized Clinical Trial. (2016, neutral): “From initial diagnosis to first FMT 91 (18-842) 82 (6-1351) 103.”
• Oral, capsulized, frozen fecal microbiota transplantation for relapsing Clostridium difficile infection. (2014, neutral): “3) [11-89] 3 (3-5) [2-6] 10 (8-15) [6-30] 5 (5-7) [2-9] 4.”
• Current understanding of dysbiosis in disease in human and animal models (2016, background): “the upper gastrointestinal tract is required for certain sporeforming Firmicutes to be effective functionally.(99) Other general concerns about FMT include safety, cost, ethical acceptance, and risks including the possible transmission of infectious agents.”
• Factors affecting the composition of the gut microbiota, and its modulation (2019, background): “However, it is less safe than rectal enemas, posing a greater risk of perforation (Kassam et al., 2013).”
• Fecal Microbiota Transplantation Induces Remission in Patients With Active Ulcerative Colitis in a Randomized Controlled Trial. (2015, methodology): “Studies that have evaluated FMT in C difficile and in inflammatory bowel disease have used a variety of routes of administration, including retention enemas, colonoscopy, and the nasoduodenal route.(14,25) We chose the retention enema approach, as”